The concentrate [Korea gimeunji financial newspaper reporter] CJ Healthcare All capabilities of the company in the synthetic drugs and biotech drug development based on the R & D.
April 1 date of its founding three years the right CJ HealthCare announced three days that progress in the third anniversary of the founding CJ talent won. In the ceremony CJ HealthCare has committed to concentrating on research and development (R & D) to accelerate future growth by innovative drug development.
CJ HealthCare finished tissue repair, including the appointment of the recent innovations drug to develop expanded its R & D organization with a full-scale reorganization, and a former CJ CJ BIO pharmaceutical strategy implemented in the R & D Business Development Director gimbyeongmun vice president.
The pharmaceutical business over 30 years has led CJ CJ CJ HealthCare has strengthened its expertise and core competencies based on accumulated R & D capabilities on April 1 last year officially launched in 2014 to grow into a global specialty pharmaceutical company.
CJ health care who have focused on the ability of the company to the development of new drugs since its launch last place being developed in October 2015, gastroesophageal reflux disease drug 'CJ-12420' technology with 100 billion won scale Gastroenterologists pharmaceutical companies in rwosin of China's leading post an exporting feat has spurred the global drug market.
CJ HealthCare has put the speed in Open Innovation activities for innovative drug pipeline will ensure the growth engine of the future. CJ HealthCare has signed an antibody drug development venture specializing in Bio-Logics wire and dual antibody drugs targeting joint research and development agreement to embellish to dig through the last forum.
In addition to the investment firm time Wise investment and 152 to million formed the 'Bio Health Care Fund, "the source was paved the way for a promising bio-ventures and investment in technology, the last three being developed dementia therapeutic antibody drug as the first investment Mon. New Oracle Sciences It has invested 20 billion.
Kang Seokhui representatives from the barn, "2016 sales of 520 billion and was the year with operating profit means achieving a 70 billion" and become a "he" pharmaceutical company with strong technology, based on accumulated R & D capability that has for the future of CJ Let's become a global pharmaceutical company that drive growth, "he ordered.
CJ HealthCare plans to focus our resources in the development of biopharmaceuticals, such as antibodies further in the New Testament synthetic drugs grown into a global pharmaceutical company with a global innovator drug. Healthcare CJ took the 2020 sales target of 1 trillion.
Daily Economic News Finance FNTIMES - commercial reprint, copy, distribute prohibited purposes under the Copyright Act
Copyright ⓒ Korea's Financial News & FNTIMES.com
